Statins & vitamins
This article was originally published in The Tan Sheet
Executive Summary
Antioxidants produced no "beneficial or adverse effects on vascular or non-vascular morbidity or mortality" in patients taking statins, University of Oxford researchers report at AHA meeting Nov. 13. Heart Protection Study comprised 20,536 subjects ages 40-80 with a history of occlusive vascular disease or diabetes. Subjects were given either 40 mg simvastatin (Merck's Zocor) or placebo daily; half of each subgroup was randomized to placebo or vitamin cocktail (600 mg vitamin E, 250 mg vitamin C, 20 mg beta carotene). Hoffman-LaRoche provided raw antioxidants, Pharmavite the finished vitamin products. Researchers report simvastatin reduced "major vascular events" in a "wide range of high-risk patients for whom there had previously been uncertainty about using cholesterol-lowering therapy," including people over 70 and those with LDL below 116mg/dL. Public health findings could have statin OTC switch implications...
You may also be interested in...
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.